{"schema_version":"secwatch.filing_event.v1","accession":"0001528287-23-000005","form_type":"8-K","ticker":"NPCE","cik":"0001528287","company_name":"NeuroPace Inc","filed_at":"2023-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.399559+00:00","generated_at":"2026-06-18T15:02:38.899633+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NeuroPace Q4 revenue $12.8M (+16% YoY); guides FY2023 revenue $50-52M","bullets":["Q4 2022 revenue $12.8M (+16% YoY); initial implant revenue $9.8M (+15% YoY).","Full year 2022 revenue $45.5M (+1% YoY); net loss $47.1M vs $36.1M in 2021.","FY2023 guidance: revenue $50-52M (10-14% growth), gross margin 69-71%, op expenses $75-77M.","DIXI Medical distribution contributed $1.6M in Q4; NAUTILUS study for primary generalized epilepsy ongoing.","Cash burn reduced to ~$15M in H2 2022 from ~$23M in H1; cash $77.4M at year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001528287-23-000005","json":"https://secwatch.observer/filing/0001528287-23-000005.json","markdown":"https://secwatch.observer/filing/0001528287-23-000005.md","text":"https://secwatch.observer/filing/0001528287-23-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/0001528287-23-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/npce-20230302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T15:02:38.899633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d75747115e27bd34ff61ccd0eb7de7dad53ddb1","claim":"NeuroPace Inc updated its Full Year 2023 guidance (initiated).","evidence_excerpt":"Full Year 2023 Financial Guidance • Total revenue to range between $50.0 million to $52.0 million, growing approximately 10% to 14% over 2022 • Gross margin to range between 69% to 71% • Total operating expenses to range between $75.0 million to $77.0 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/0001528287-23-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"77b2a64916f6c6564f803ddde5ee5a6c1dc04969","claim":"NeuroPace Inc reported the full year ended December 31, 2022 results: EPS not provided.","evidence_excerpt":"On March 2, 2023, NeuroPace, Inc. issued a press release announcing its financial results for the fiscal quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/0001528287-23-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"EPS","value":"not provided"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"77b2a64916f6c6564f803ddde5ee5a6c1dc04969","claim":"NeuroPace Inc reported the full year ended December 31, 2022 results: EPS not provided.","evidence_excerpt":"Total revenue was $45.5 million in 2022, representing growth of 1% compared to 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/0001528287-23-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"EPS","value":"not provided"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"77b2a64916f6c6564f803ddde5ee5a6c1dc04969","claim":"NeuroPace Inc reported the full year ended December 31, 2022 results: EPS not provided.","evidence_excerpt":"Net loss was $47.1 million for 2022, compared to a net loss of $36.1 million in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/0001528287-23-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"EPS","value":"not provided"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"85f7e32da51e27d8e539de3babfa353d2697595c","claim":"NeuroPace Inc reported the fourth quarter ended December 31, 2022 results: EPS not provided.","evidence_excerpt":"On March 2, 2023, NeuroPace, Inc. issued a press release announcing its financial results for the fiscal quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/0001528287-23-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"EPS","value":"not provided"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"85f7e32da51e27d8e539de3babfa353d2697595c","claim":"NeuroPace Inc reported the fourth quarter ended December 31, 2022 results: EPS not provided.","evidence_excerpt":"Total revenue was $12.8 million in the fourth quarter of 2022, representing growth of 16% compared to the prior year period and 15% compared to the prior quarter.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/0001528287-23-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"EPS","value":"not provided"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"85f7e32da51e27d8e539de3babfa353d2697595c","claim":"NeuroPace Inc reported the fourth quarter ended December 31, 2022 results: EPS not provided.","evidence_excerpt":"Net loss was $11.1 million for the fourth quarter of 2022, compared to a net loss of $10.7 million in the prior year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000005/0001528287-23-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"EPS","value":"not provided"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}